Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan;41(1):25-30.
doi: 10.1016/j.ejcts.2011.04.010.

Pulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy

Tatsuro Okamoto  1 , Takekazu Iwata, Teruaki Mizobuchi, Hidehisa Hoshino, Yasumitsu Moriya, Shigetoshi Yoshida, Ichiro Yoshino
Affiliations

Pulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy

Tatsuro Okamoto et al. Eur J Cardiothorac Surg. 2012 Jan.

Abstract

Objectives: The prognosis of non-small-cell lung cancer (NSCLC) patients with malignant pleural disease (MPD), characterized by malignant pleural effusion and/or malignant pleural nodules, is reported to be poor, and patients with MPD are generally not subjected to surgery. However, whether or not the primary tumor should be resected, when MPD is first detected at thoracotomy, is controversial.

Methods: The clinical records of 1623 consecutive NSCLC patients, who underwent surgery between 1990 and 2007, were retrospectively reviewed. A hundred patients (6.2%) were classified with pathological stage IV disease according to the seventh edition of the Union for International Cancer Control (UICC) staging system. There were 73 patients with MPD, which included 32 with effusion without nodules (MPE) and 41 with nodules with or without effusion (MPN). Intra- or postoperative pleural chemotherapy was administered to 37 MPD patients.

Results: The median survival time, the 3-year survival rate and the 5-year survival rate for MPD patients were 25.9 months, 41.4%, and 23.7%, respectively, which are better outcomes than those for M1b patients (8.7 months, 18% and 18%, respectively) (log-lank test: p=0.014). Among MPD patients, N0-1 disease was determined to be a favorable prognostic factor (p=0.01). MPD status (MPE or MPN) was not prognostically significant (p=0.40). MPE patients with N0-1 disease had a significantly better prognosis with a 5-year survival rate of 63.6% compared to MPE patients with N2-3 disease (p=0.003). Twenty-seven percent of MPN patients with N0-1 disease achieved 5-year survival, whereas none of the MPD patients with N2-3 disease survived longer than 5 years after surgery.

Conclusions: The prognosis of patients with surgically detected MPD, who underwent resection, was better than that of M1b patients. MPE patients with N0-1 disease may be candidates for resection.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
(A) Postoperative survival curves of patients with malignant pleural disease (MPD) and patients with distant metastasis (M1b); (B) postoperative survival curves of patients with malignant pleural effusion without nodules (MPE), patients with malignant pleural nodules with or without effusion (MPN) and patients with distant metastasis (M1b). (MST = median survival time).
Figure 2:
Figure 2:
(A) Postoperative survival curves of patients with malignant pleural disease (MPD) according to N status; (B) postoperative survival curves of patients with malignant pleural effusion without nodules (MPE) and patients with malignant pleural nodules with or without effusion (MPN) stratified by N status. (MST = median survival time).
See this image and copyright information in PMC

References

    1. Sugiura S, Ando Y, Minami H, Ando M, Sakai S, Shimokata K. Prognostic value of pleural effusion in patients with non-small cell lung cancer. Clin Cancer Res. 1997;3:47–50. - PubMed
    1. Jett JR, Scott WJ, Rivera MP, Sause WT American College of Chest Physicians. Guidelines on treatment of stage IIIB non-small cell lung cancer. Chest. 2003;123:221S–5S. - PubMed
    1. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2:706–14. - PubMed
    1. Sobin LH, Gospodarowicz MK, Wittekind C, International Union Against Cancer . 7th ed. Oxford, UK: Wiley-Blackwell; 2009. TNM classification of malignant tumours. p. 138–46.
    1. Heffner JE, Klein JS. Recent advances in the diagnosis and management of malignant pleural effusions. Mayo Clin Proc. 2008;83:235–50. - PubMed

MeSH terms